BOSTON, May 7, 2024
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an
innovative oncology company focused on the discovery and
development of selective cancer therapies to treat patients across
a range of solid tumors with significant unmet medical needs, today
announced that Joseph J. Ferra,
Chief Executive Officer of Elevation Oncology, will participate in
a fireside chat at the Citizens JMP Life Sciences Conference on
Tuesday, May 14, 2024, at
11:30 am ET.
A live webcast and replay of the event will be available on the
Events page of the Company's Investor Relations website at
https://investors.elevationoncology.com.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on
the discovery and development of selective cancer therapies to
treat patients across a range of solid tumors with significant
unmet medical needs. We are leveraging our antibody-drug conjugate
(ADC) expertise to advance a novel pipeline, initially targeting
two clinically validated targets in oncology, Claudin 18.2 and
HER3. Our lead candidate, EO-3021, is a potential best-in-class ADC
designed to target Claudin 18.2 and is currently being evaluated in
a Phase 1 trial (NCT05980416) in patients with advanced,
unresectable or metastatic solid tumors likely to express Claudin
18.2 including gastric, gastroesophageal junction, pancreatic or
esophageal cancers. Additionally, we expect to nominate a
development candidate for our second program, a HER3-targeting ADC
for the treatment of patients with solid tumors that overexpress
HER3, in 2024. For more information, visit
www.ElevationOncology.com.
Elevation Oncology Investor and Media Contact
Hannah Deresiewicz, 212-362-1200
EVP, Managing Director, Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-citizens-jmp-life-sciences-conference-302137883.html
SOURCE Elevation Oncology